Abstract
Purpose
Many studies report that pancreatoduodenectomy (PD) with portal-superior mesenteric vein resection and reconstruction (PVR) is not a contraindication to extended tumor resection for pancreatic ductal adenocarcinoma. However, the clinical benefit of an interposition graft for PVR still remains controversial.
Methods
Between January 2001 and December 2017, 199 patients with pancreatic cancer underwent PD either with or without PVR, and their medical records were reviewed retrospectively, paying specific attention to the PVR methods and the long-term outcome.
Results
Among the 122 patients with PVR, 97 (79.5%) underwent end-to-end anastomosis and 25 (20.5%) had an interposition graft using the right external iliac vein (REIV). The 2-year and 5-year survival rates of the no-PVR group (54.2% and 30.8%, respectively) were longer than both the end-to-end anastomosis group (24.5% and 13.7%) and the interposition graft group (32% and 10.0%) (p < 0.001). However, there was no significant difference in the survival between the end-to-end anastomosis group and the interposition graft group (p = 0.963). A multivariate analysis indicated that the level of preoperative serum albumin < 3.5 g/dL (risk ratio (RR) 2.08, 95% confidence interval (CI) 1.26 to 3.43; p = 0.004), and postoperative adjuvant chemotherapy (RR 1.82, 95% CI 1.19 to 2.79; p = 0.006) were independently associated with overall survival after PVR.
Conclusions
An interposition graft using the REIV for PVR following PD is safe and effective. There was no significant prognostic difference between PD with end-to-end anastomosis and with an interposition graft in patients with pancreatic ductal adenocarcinoma.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.References
Roch AM, House MG, Cioffi J, Ceppa EP, Zyromski NJ, Nakeeb A et al (2016) Significance of portal vein invasion and extent of invasion in patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma. J Gastrointest Surg 20(3):479–487
Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, Sinn M, Hinke A, Riess H (2013) Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310(14):1473–1481
Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y (2016) JASPAC 01 Study Group. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388(10041):248–257
Bell R, Ao BT, Ironside N, Bartlett A, Windsor JA, Pandanaboyana S (2017) Meta-analysis and cost effective analysis of portal-superior mesenteric vein resection during pancreatoduodenectomy: impact on margin status and survival. Surg Oncol 26(1):53–62
Giovinazzo F, Turri G, Katz MH, Heaton N, Ahmed I (2016) Meta-analysis of benefits of portal-superior mesenteric vein resection in pancreatic resection for ductal adenocarcinoma. Br J Surg 103(3):179–191
Murakami Y, Satoi S, Motoi F, Sho M, Kawai M, Matsumoto I (2015) Portal or superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head carcinoma. Br J Surg 102(7):837–846
Klein F, Berresheim F, Felsenstein M, Malinka T, Pelzer U, Denecke T, Pratschke J, Bahra M (2018) Routine portal vein resection for pancreatic adenocarcinoma shows no benefit in overall survival. Eur J Surg Oncol 44(7):1094–1099
Snyder RA, Prakash LR, Nogueras-Gonzalez GM, Kim MP, Aloia TA, Vauthey JN, Lee JE, Fleming JB, Katz MHG, Tzeng CWD (2018) Vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: patency rates and outcomes associated with thrombosis. J Surg Oncol 117(8):1648–1654
Yekebas EF, Bogoevski D, Cataldegirmen G, Kunze C, Marx A, Vashist YK, Schurr PG, Liebl L, Thieltges S, Gawad KA, Schneider C, Izbicki JR (2008) En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients. Ann Surg 247(2):300–309
Wang C, Wu H, Xiong J, Zhou F, Tao J, Liu T, Zhao G, Gou S (2008) Pancreaticoduodenectomy with vascular resection for local advanced pancreatic head cancer: a single center retrospective study. J Gastrointest Surg 12(12):2183–2190
Ravikumar R, Sabin C, Abu Hilal M, Al-Hilli A, Aroori S, Bond-Smith G et al (2017) Impact of portal vein infiltration and type of venous reconstruction in surgery for borderline resectable pancreatic cancer. Br J Surg 104(11):1539–1548
Society JP (ed) (2003) General rules for the study of pancreatic cancer, 2nd edn. Kanehara, Tokyo
Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250:187–196
Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA et al (2014) International Study Group of Pancreatic Surgery. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 155(6):977–988
Leach SD, Lee JE, Charnsangavej C, Cleary KR, Lowy AM, Fenoglio CJ et al (1998) Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 85(5):611–617
Bachellier P, Nakano H, Oussoultzoglou PD, Weber JC, Boudjema K, Wolf PD et al (2001) Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile? Am J Surg 182(2):120–129
Shimoda M, Mori S, Kita J, Sawada T, Kubota K (2013) Results of pancreaticoduodenectomy with portal or superior mesenteric vein resection for locally advanced pancreatic head cancer. Hepatogastroenterology 60(128):2094–2098
Ramacciato G, Mercantini P, Petrucciani N, Giaccaglia V, Nigri G, Ravaioli M, Cescon M, Cucchetti A, del Gaudio M (2009) Does portal-superior mesenteric vein invasion still indicate irresectability for pancreatic carcinoma? Ann Surg Oncol 16(4):817–825
Kaneoka Y, Yamaguchi A, Isogai M (2009) Portal or superior mesenteric vein resection for pancreatic head adenocarcinoma: prognostic value of the length of venous resection. Surgery 145(4):417–425
Takahashi S, Ogata Y, Aiura K, Kitajima M, Hiramatsu K (2000) Combined resection of the portal vein for pancreatic cancer: preoperative diagnosis of invasion by portography and prognosis. Hepatogastroenterology 47(32):545–549
Boggi U, Del Chiaro M, Croce C, Vistoli F, Signori S, Moretto C et al (2009) Prognostic implications of tumor invasion or adhesion to peripancreatic vessels in resected pancreatic cancer. Surgery 146(5):869–881
Han SS, Park SJ, Kim SH, Cho SY, Kim YK, Kim TH, Lee SA, Woo SM, Lee WJ, Hong EK (2012) Clinical significance of portal-superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head cancer. Pancreas 41(1):102–106
Konstantinidis IT, Warshaw AL, Allen JN, Blaszkowsky LS, Castillo CF, Deshpande V, Hong TS, Kwak EL, Lauwers GY, Ryan DP, Wargo JA, Lillemoe KD, Ferrone CR (2013) Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a “true” R0 resection? Ann Surg 257(4):731–736
Strobel O, Hank T, Hinz U, Bergmann F, Schneider L, Springfeld C, Jäger D, Schirmacher P, Hackert T, Büchler MW (2017) Pancreatic cancer surgery: the new R-status counts. Ann Surg 265(3):565–573
Delpero JR, Jeune F, Bachellier P, Regenet N, Le Treut YP, Paye F et al (2017) Prognostic value of resection margin involvement after pancreaticoduodenectomy for ductal adenocarcinoma: updates from a French prospective multicenter study. Ann Surg 266(5):787–796
Marchegiani G, Andrianello S, Malleo G, De Gregorio L, Scarpa A, Mino-Kenudson M et al (2017) Does size matter in pancreatic cancer?: reappraisal of tumour dimension as a predictor of outcome beyond the TNM. Ann Surg 266(1):142–148
Butturini G, Stocken DD, Wente MN, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Dervenis C, Bassi C, Büchler MW, Neoptolemos JP, Pancreatic Cancer Meta-Analysis Group (2008) Pancreatic Cancer Meta-Analysis Group. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 143(1):75–83
Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Büchler MW (2017) European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389(10073):1011–1024
Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, Waldschmidt D, Jacobasch L, Wilhelm M, Rau BM, Grützmann R, Weinmann A, Maschmeyer G, Pelzer U, Stieler JM, Striefler JK, Ghadimi M, Bischoff S, Dörken B, Oettle H, Riess H (2017) CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. J Clin Oncol 35(29):3330–3337
Hendifar A, Osipov A, Khanuja J, Nissen N, Naziri J, Yang W, Li Q, Tuli R (2016) Influence of body mass index and albumin on perioperative morbidity and clinical outcomes in resected pancreatic adenocarcinoma. PLoS One 11(3):e0152172
Wang F, Arianayagam R, Gill A, Puttaswamy V, Neale M, Gananadha S, Hugh TJ, Samra JS (2012) Grafts for mesenterico-portal vein resections can be avoided during pancreatoduodenectomy. J Am Coll Surg 215(4):569–579
Zhang J, Qian HG, Leng JH, Cui M, Qiu H, Zhou GQ, Wu JH, Yang Y, Hao CY (2009) Long mesentericoportal vein resection and end-to-end anastomosis without graft in pancreaticoduodenectomy. J Gastrointest Surg 13(8):1524–1528
Dua MM, Tran TB, Klausner J, Hwa KJ, Poultsides GA, Norton JA, Visser BC (2015) Pancreatectomy with vein reconstruction: technique matters. HPB (Oxford) 17(9):824–831
Ochiai T, Masuda T, Nishizawa M, Ito H, Igari K, Aihara A, Kumagai Y, Iida M, Odajima H, Arii S, Yamazaki S (2011) Curative resection of a huge malignant pancreatic endocrine tumor by pancreatoduodenectomy with portal and superior mesenteric vein resection and reconstruction using the right ovarian vein: report of a case. Surg Today 41(9):1260–1265
Yamamoto Y, Sakamoto Y, Nara S, Ban D, Esaki M, Shimada K, Kosuge T (2009) Reconstruction of the portal and hepatic veins using venous grafts customized from the bilateral gonadal veins. Langenbeck's Arch Surg 394(6):1115–1121
Lee DY, Mitchell EL, Jones MA, Landry GJ, Liem TK, Sheppard BC, Billingsley KG, Moneta GL (2010) Techniques and results of portal vein/superior mesenteric vein reconstruction using femoral and saphenous vein during pancreaticoduodenectomy. J Vasc Surg 51(3):662–666
Chu CK, Farnell MB, Nguyen JH, Stauffer JA, Kooby DA, Sclabas GM, Sarmiento JM (2010) Prosthetic graft reconstruction after portal vein resection in pancreaticoduodenectomy: a multicenter analysis. J Am Coll Surg 211(3):316–324
Stauffer JA, Dougherty MK, Kim GP, Nguyen JH (2009) Interposition graft with polytetrafluoroethylene for mesenteric and portal vein reconstruction after pancreaticoduodenectomy. Br J Surg 96(3):247–252
Kaneoka Y, Maeda A, Sugimoto M, Isogai M, Ishibashi H (2013) Quality of life and the venous function of the lower limb after harvest of autologous external iliac vein grafts: a clinical follow-up study. Surg Today 43(11):1254–1260
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Terasaki, F., Fukami, Y., Maeda, A. et al. Comparison of end-to-end anastomosis and interposition graft during pancreatoduodenectomy with portal vein reconstruction for pancreatic ductal adenocarcinoma. Langenbecks Arch Surg 404, 191–201 (2019). https://doi.org/10.1007/s00423-019-01749-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00423-019-01749-2